6533b7ddfe1ef96bd1273ff4

RESEARCH PRODUCT

Melatonin levels in Parkinson's disease: Drug therapy versus electrical stimulation of the internal globus pallidus

A. IradiM.d. CatalaC. Cañete-nicolásFrancisco TarazonaAlvaro Pascual-leoneJosé María Tormos

subject

endocrine systemAgingmedicine.medical_specialtyParkinson's diseaseElectric Stimulation TherapyStimulationGlobus PallidusBiochemistryAntiparkinson AgentsMelatoninEndocrinologyPharmacotherapyInternal medicineGeneticsmedicineHumansIn patientCircadian rhythmMolecular BiologyMelatoninInternal globus pallidusbusiness.industryParkinson DiseaseCell Biologymedicine.diseaseCircadian RhythmEndocrinologyGlobus pallidusbusinesshormones hormone substitutes and hormone antagonistsmedicine.drug

description

The objective of our work was to measure plasma melatonin levels in patients with Parkinson's Disease (PD) following electrical stimulation of the internal globus pallidus (GPi), and to compare these levels with groups of PD patients under drug therapy and healthy controls. The levels of melatonin were measured twice daily at 1000 and 1200. The GPi stimulation at 130 Hz lowered melatonin levels, while no changes were observed in the absence of stimulation. The melatonin levels from healthy subjects were lower than those observed in PD patients. The melatonin levels from PD patients under drug therapy were also measured during the night (2000-2400-0400) and at 0800 in order to observe their circadian changes. The Internal Globus Pallidus (GPi) stimulation was effective in lowering the melatonin levels during the day and, therefore returned these levels to those observed in normal subjects.

yearjournalcountryeditionlanguage
1997-07-01Experimental Gerontology
https://doi.org/10.1016/s0531-5565(96)00173-8